Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares MSCI Indonesia ETF — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B), while iShares MSCI Indonesia ETF trades at $12. The key difference: Bristol-Myers Squibb Co pays a 4.25% dividend while iShares MSCI Indonesia ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| BMY | EIDO | |
|---|---|---|
Market Cap | $121.18B | — |
Sector | Health | — |
52-Week High | $62.37 | $19.22 |
52-Week Low | $42.60 | $10.80 |
Enterprise Value | $157.12B | — |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EIDO, the iShares MSCI Indonesia ETF, trades at $11.98, up 1.1% on the day, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. Key financial ratios are unavailable, but recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah. The ETF's dividend dropped 27% in 2025, indicating potential income instability for investors.
The outlook for EIDO is mixed, with opportunities from Indonesia's GDP growth potential but risks from currency volatility and dividend cuts. Investors face headwinds from bearish technical signals and macroeconomic pressures, requiring careful assessment of emerging market exposure amid fluctuating sentiment and limited fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
